Azilsartan medoxomil: A new angiotensin receptor blocker

Clinical Therapeutics

Volumn 33, Issue 11, 2011, Pages 1577-1589

  Zaiken, Kathy ^a   Cheng, Judy W M ^a  

^a MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

Angiotensin receptor blocker; Azilsartan medoxomil; Hypertension

Indexed keywords

AMLODIPINE; ANTACID AGENT; AZILSARTAN MEDOXOMIL; CAFFEINE; CANDESARTAN; CANDESARTAN HEXETIL; CHLORTALIDONE; DEXTROMETHORPHAN; EPROSARTAN; FEXOFENADINE; FLUCONAZOLE; GLIBENCLAMIDE; IRBESARTAN; KETOCONAZOLE; LOSARTAN; LOSARTAN POTASSIUM; METFORMIN; MIDAZOLAM; OLMESARTAN; PIOGLITAZONE; PLACEBO; RAMIPRIL; TELMISARTAN; TOLBUTAMIDE; VALSARTAN;

DIABETIC NEPHROPATHY; DIARRHEA; DIZZINESS; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG METABOLISM; DRUG SAFETY; DYSLIPIDEMIA; FOOD AND DRUG ADMINISTRATION; HEADACHE; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; HYPOTENSION; LIFESTYLE MODIFICATION; ORTHOSTATIC HYPOTENSION; PEER REVIEW; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTOLIC BLOOD PRESSURE; URINARY TRACT INFECTION;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; HUMANS; HYPERTENSION; OXADIAZOLES;

EID: 82855179445     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.10.007     Document Type: Review

References (28)

1. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure US Department of Health and Human Services, Accessed August 24, 2011. http://www.nhlbi.nih.gov/guidelines/hypertension/jnc7full.pdf.
2. Lloyd-Jones D., Adams R.J., Brown T.M., et al. Heart disease and stroke statistics-2010 update. A report from the American Heart Association statistics committee and stroke statistics committee. Circulation 2010, 121:e1-e170.
3. High Blood Pressure Facts Centers for Disease Control and Prevention, Accessed July 24, 2011. http://www.cdc.gov/bloodpressure/facts.htm.
4. Staessen J.A., Wang J., Bianchi G., Birkenhager W.H. Essential hypertension. Lancet 2003, 361:1629-1641.
5. Kaplan N.M. Kaplan's Clinical Hypertension 2006, Lippincott Williams & Wilkins, Philadelphia, Pa. 9th ed.
6. Ojima M., Hideki I., Masayuki T., et al. In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies. J Pharmacol Exp Ther 2011, 336:801-808.
7. Cushman W.C., Ford C.E., Cutler J.A., et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich) 2002, 4:393-404.
8. Black H.R., Elliott W.J., Neaton J.D., et al. Baseline characteristics and elderly blood pressure control in the CONVINCE trial. Hypertension 2001, 37:12-18.
9. Edarbi [prescribing information] 2011, Takeda Pharmaceuticals America, Inc, Deerfield, Ill, Accessed July 7, 2011. http://www.edarbi.com/.
10. Atacand tablets [prescribing information] 2009, AstraZeneca LP, Wilmington, Del.
11. Avapro tablets [prescribing information] 2005, Bristol-Myers-Squibb/Sanofi-Synthelabo Partnership, New York, NY.
12. Benicar [prescribing information] 2002, Sankyo Pharma, New York, NY.
13. Cozaar tablets [prescribing information] 2010, Merck Sharp & Dohme Corp, Whitehouse Station, NJ.
14. Diovan tablets [prescribing information] 2007, Novartis Pharmaceuticals Corp, East Hanover, NJ.
15. Micardis [prescribing information] 1998, Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, Conn.
16. Teveten tablets [prescribing information] 2004, Biovail Pharmaceuticals, Inc, Bridgewater, NJ.
17. Clinical Pharmacology and Biopharmaceutics Review(s). NDA 200-796: Azilsartan medoxomil Center for Drug Evaluation and Research, Accessed July 26, 2011. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/200796Orig1s000ClinPharmR.pdf.
18. Agrawal M., Swartz R. Acute renal failure. Am Fam Physician 2000, 61:2077-2088.
19. Bakris G.L., Sica D., Weber M., et al. The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinical blood pressure. J Clin Hypertens (Greenwich) 2011, 13:81-88.
20. White W.B., Weber M.A., Sica D., et al. Effects of angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stage 1 and 2 hypertension. Hypertension 2011, 57:413-420.
21. Sica D., White W.B., Weber M.A., et al. Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring. J Clin Hypertens (Greenwich) 2011, 13:467-472.
22. Medical Review(s). NDA: 200796 Azilsartan medoxomil (Edarbi) for hypertension Center for Drug Evaluation and Research, Accessed July 7, 2011. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/200796Orig1s000MedR.pdf.
23. Drug prices and information Drugstore.com, Edarbi, Accessed August 4, 2011. http://www.drugstore.com/edarbi/bottle-30-80mg-tablets/qxn64764088430.
24. Linn W.D. Angiotensin-converting enzyme inhibitors in left ventricular dysfunction. Pharmacotherapy 1996, 16:50S-58S.
25. Maggioni A.P. Efficacy of angiotensin receptor blockers in cardiovascular disease. Cardiovasc Drugs Ther 2006, 20:295-308.
26. Hilleman D.E., Lucas B.D. Angiotensin-converting enzyme inhibitors and stroke risk: benefit beyond blood pressure reduction?. Pharmacotherapy 2004, 24:1064-1076.
27. Strippoli G.F., Craig M., Deeks J.J., et al. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systemic review. BMJ 2004, 329:825-836.
28. Greenberg B., Zannad F., Pitt B. Role of aldosterone blockade for treatment of heart failure and post-acute myocardial infarction. Am J Cardiol 2006, 97(10A):34F-40F.